Trial · NCT07912177
Family Accommodation Reduction in Adult Obsessive Compulsive Disorder
NCT07912177, Not applicable, Enrolling by invitation, Karen Rowa
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Family Accommodation Reduction in Adult Obsessive Compulsive Disorder. Trials, record NCT07912177. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912177
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Family Accommodation Reduction in Adult Obsessive Compulsive Disorder
- NCT number
- NCT07912177
- Status
- Enrolling by invitation
- Phases
- Not applicable
- Enrollment
- 480 participants, estimated
- Lead sponsor
- Karen Rowa
- Conditions
- Obsessive - Compulsive Disorder, Family Accommodation, OCD, CBT, Psychoeducation
- Interventions
- Family Accommodation Reduction, Family Psychoeducation
- First posted
- 2026-11-03
- Last updated
- 2026-11-06
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in OCD Symptom Severity from Baseline to 3-Months Post-Treatment (Patient Self-Report) | Baseline to 3-Months Post-Treatment | OCD symptom severity is measured by the self-report Yale-Brown Obsessive-Compulsive Scale, Second Edition (Y-BOCS-II; Storch et al., 2010). The Y-BOCS-II has 10 items pertaining to obsessions and compulsions rated on a Likert scale. Scores range from 0 to 40 with higher scores indicating increased symptom severity. |
| Primary | Change in Quality of Life from Baseline to 3-Months Post-Treatment (Patient Self-Report) | Baseline to 3-Months Post-Treatment | Quality of life is measured by the Illness Intrusiveness Rating Scale (IIRS; Devins, 1994). The IIRS is a 13-item self-report measure of the degree to which symptoms interfere with important life domains (e.g., work, family relationships). Total scores range from 13 (minimum intrusiveness) to 91 (extreme intrusiveness). |
| Primary | Change in Functional Impairment from Baseline to 3-Months Post-Treatment (Patient Self-Report) | Baseline to 3-Months Post-Treatment | Functional Impairment is measured by: 1. The Sheehan Disability Scale (SDS; Sheehan et al., 1983). The SDS is a brief measure of disability and functional impairment due to psychiatric or medical symptoms focused on work, social life/leisure activities, and family life/home responsibilities. Scores range from 0 (unimpaired) to 30 (highly impaired). 2. The Family Functioning Scale (FFS; Stewart et al., 2017). The FFS is a self-report scale of how much family impairment arises from OCD symptoms. Scores range from 0 to 63 with higher scores indicating increased family impairment. |
| Secondary | Change in Family Accommodation from Baseline to 3-Months Post-Treatment (Family Member Self- Report) | Baseline to 3-Months Post-Treatment | Family Accommodation is measured by the Family Accommodation Scale for Obsessive-Compulsive Disorder - Self-Rated Version (FAS-SR, Pinto et al., 2013). The FAS-SR is a 19-item self-report measure that gathers information about the degree to which family members participate in accommodating behaviours. Scores range from 0 to 76 with higher scores indicating more family accommodation. |
| Secondary | Change in Family Accommodation from Baseline to 3-Months Post-Treatment (Patient Self- Report) | Baseline to 3-Months Post-Treatment | Family Accommodation is measured by the Family Accommodation Scale for Obsessive-Compulsive Disorder - Patient Version (FAS-PV; Wu et al., 2016) is a 19-item self-report measure that gathers information about the degree to which an OCD patient's family member participates in accommodating behaviours. Scores range from 0 to 76 with higher scores indicating more family accommodation. |
| Secondary | Change in OCD Symptom Severity from Baseline to 3-Months Post-Treatment (Family Member Self-Report) | Baseline to 3-Months Post-Treatment | OCD symptom severity is measured by the self-report Yale-Brown Obsessive-Compulsive Scale, Second Edition (Y-BOCS-II; Storch et al., 2010). This will be administered to family members as well given the tendency for OCD symptoms to cluster within families. The Y-BOCS-II has 10 items pertaining to obsessions and compulsions rated on a Likert scale. Scores range from 0 to 40 with higher scores indicating increased symptom severity. |
| Secondary | Change in Severity of Depression, Anxiety, and Stress from Baseline to 3-Months Post-Treatment (Patient Self-Report) | Baseline to 3-Months Post-Treatment | The Depression Anxiety Stress Scale-21 (DASS-21; Lovibond \& Lovibond, 1995) is a 21-item self-report measure designed to assess the severity of depression, anxiety, and stress symptoms. Scores range from 0 to 63 on each of the subscales (Depression, Anxiety, and Stress), with higher scores indicating increased symptom severity. |
| Secondary | Change in Severity of Depression, Anxiety, and Stress from Baseline to 3-Months Post-Treatment (Family Member Self-Report) | Baseline to 3-Months Post-Treatment | The Depression Anxiety Stress Scale-21 (DASS-21; Lovibond \& Lovibond, 1995) is a 21-item self-report measure designed to assess the severity of depression, anxiety, and stress symptoms. Scores range from 0 to 63 on each of the subscales (Depression, Anxiety, and Stress), with higher scores indicating increased symptom severity. |
| Secondary | Change in Quality of Life from Baseline to 3-Months Post-Treatment (Family Member Self-Report) | Baseline to 3-Months Post-Treatment | Quality of life is measured by the Illness Intrusiveness Rating Scale (IIRS; Devins, 1994). The IIRS is a 13-item self-report measure of the degree to which symptoms interfere with important life domains (e.g., work, family relationships). Total scores range from 13 (minimum intrusiveness) to 91 (extreme intrusiveness). |
| Secondary | Change in Functional Impairment from Baseline to 3-Months Post-Treatment (Family Member Self-Report) | Baseline to 3-Months Post-Treatment | Functional Impairment is measured by the Sheehan Disability Scale (SDS; Sheehan et al., 1983). The SDS is a brief measure of disability and functional impairment due to psychiatric or medical symptoms focused on work, social life/leisure activities, and family life/home responsibilities. Scores range from 0 (unimpaired) to 30 (highly impaired). |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912177
GET https://conductscience.org/api/trials/v1/NCT07912177/registered